Lupin Manufacturing Solutions Expands Dabhasa Facility to Strengthen CRDMO Capabilities

Lupin Manufacturing Solutions (LMS), a subsidiary of global pharma major Lupin Limited, has announced a strategic expansion of its Dabhasa manufacturing facility. This expansion aims to scale its peptide building-blocks platform and CRDMO capabilities, featuring a new block to enhance existing CRDMO capabilities and dedicated peptide manufacturing capacity across two additional specialized units. The upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions. LMS is committed to building advanced, scalable capabilities that support complex development programs and reinforce its role in the global peptide ecosystem, enabling meaningful partnerships with innovators worldwide.